{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T12:03:12Z","timestamp":1795262592774,"version":"4.10.3"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"am","delay-in-days":292,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS117209"],"award-info":[{"award-number":["U01NS117209"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS117278"],"award-info":[{"award-number":["U01NS117278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0660"],"award-info":[{"award-number":["W81XWH-16-1-0660"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0305"],"award-info":[{"award-number":["W81XWH-21-1-0305"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0311"],"award-info":[{"award-number":["W81XWH-21-1-0311"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0314"],"award-info":[{"award-number":["W81XWH-21-1-0314"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007904","name":"Texas A and M University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.expneurol.2022.114238","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T01:59:56Z","timestamp":1664848796000},"page":"114238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"359","author":[{"given":"Ashna","family":"Talwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Estes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doodipala Samba","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.expneurol.2022.114238_bb0005","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s12098-014-1533-1","article-title":"Refractory epilepsy in children","volume":"81","author":"Aneja","year":"2014","journal-title":"Indian J. Pediatr."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114238_bb0010","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/head.12570","article-title":"Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip It\u2019s been \u2026","volume":"55","author":"Baron","year":"2015","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.expneurol.2022.114238_bb0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/epi.16542","article-title":"Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.expneurol.2022.114238_bb0020","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","article-title":"Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2022.114238_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.734612","article-title":"Treatment guidelines for rare, early-onset, treatment-resistant epileptic conditions: a literature review on Dravet syndrome, Lennox-Gastaut syndrome and CDKL5 deficiency disorder","volume":"12","author":"Chin","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.expneurol.2022.114238_bb0030","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1124\/pr.119.017392","article-title":"Sex differences in the epilepsies and associated comorbidities: implications for use and development of pharmacotherapies","volume":"72","author":"Christine","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114238_bb0035","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbadis.2017.02.003","article-title":"Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy","volume":"1863","author":"Clossen","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.expneurol.2022.114238_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106635","article-title":"Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis","volume":"102","author":"de Carvalho Reis","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114238_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","article-title":"Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies","volume":"35","author":"De Leon","year":"2013","journal-title":"Ther. Drug Monit."},{"issue":"19","key":"10.1016\/j.expneurol.2022.114238_bb0055","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMra1010481","article-title":"Sudden, unexpected death in epilepsy","volume":"365","author":"Devinsky","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2022.114238_bb0060","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia."},{"issue":"21","key":"10.1016\/j.expneurol.2022.114238_bb0065","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.expneurol.2022.114238_bb0070","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.expneurol.2022.114238_bb0075","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.expneurol.2022.114238_bb0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurol. Scand."},{"issue":"11","key":"10.1016\/j.expneurol.2022.114238_bb0085","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jid.2016.08.021","article-title":"Research techniques made simple: assessing risk of Bias in systematic reviews","volume":"136","author":"Drucker","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.expneurol.2022.114238_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.121.000994","article-title":"Therapeutic basis of generic substitution of antiseizure medications","volume":"381","author":"Elmer","year":"2022","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"10.1016\/j.expneurol.2022.114238_bb0095","author":"FDA"},{"issue":"Pt A","key":"10.1016\/j.expneurol.2022.114238_bb0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.yebeh.2019.07.008","article-title":"Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label expanded access program","volume":"98","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114238_bb0105","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1017\/S0012162206000843","article-title":"Aggravation of epilepsy by antiepileptic drugs","volume":"48","author":"Gayatri","year":"2006","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.expneurol.2022.114238_bb0110","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114238_bb0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.expneurol.2022.114238_bb0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-030-57369-0_7","article-title":"Cannabidiol therapy for refractory epilepsy and seizure disorders","volume":"1264","author":"Golub","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114238_bb0125","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.13351","article-title":"Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials","volume":"143","author":"Gunning","year":"2021","journal-title":"Acta Neurol. Scand."},{"issue":"7414","key":"10.1016\/j.expneurol.2022.114238_bb0130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"issue":"13","key":"10.1016\/j.expneurol.2022.114238_bb0135","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.expneurol.2022.114238_bb0140","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","article-title":"Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis","volume":"32","author":"Lattanzi","year":"2018","journal-title":"CNS Drugs"},{"issue":"17","key":"10.1016\/j.expneurol.2022.114238_bb0145","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.expneurol.2022.114238_bb0150","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/epi.16546","article-title":"Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis","volume":"61","author":"Lattanzi","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114238_bb0155","first-page":"673","article-title":"Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome","volume":"7","author":"Leahy","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114238_bb0160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.expneurol.2022.114238_bb0165","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.expneurol.2022.114238_bb0170","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"349","article-title":"Assessing risk of bias due to missing results in a synthesis","author":"Page","year":"2019"},{"key":"10.1016\/j.expneurol.2022.114238_bb0175","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114238_bb0180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/ecp.10.3","article-title":"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives","volume":"3","author":"Reddy","year":"2010","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114238_bb0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pbb.2016.07.002","article-title":"The neuroendocrine basis of sex differences in epilepsy","volume":"152","author":"Reddy","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114238_bb0190","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cpt.441","article-title":"The utility of cannabidiol in the treatment of refractory epilepsy","volume":"101","author":"Reddy","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114238_bb0195","first-page":"5165","article-title":"Clinical pharmacology and therapeutics of antiepileptic drugs for epilepsy and seizure disorders","volume":"13","author":"Reddy","year":"2020","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"key":"10.1016\/j.expneurol.2022.114238_bb0200","first-page":"#22","article-title":"Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies","author":"Reddy","year":"2022","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114238_bb0205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114238_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135753","article-title":"Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis","volume":"750","author":"Reddy","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2022.114238_bb0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jclinepi.2017.11.025","article-title":"Between-trial heterogeneity in meta-analyses may be partially explained by reported design characteristics","volume":"95","author":"Rhodes","year":"2018","journal-title":"J. Clin. Epidemiol."},{"issue":"Pt A","key":"10.1016\/j.expneurol.2022.114238_bb0220","article-title":"Reduced efficacy and risk of seizure aggravation when cannabidiol is used without clobazam","volume":"103","author":"Rogawski","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.expneurol.2022.114238_bb0225","doi-asserted-by":"crossref","first-page":"106263","DOI":"10.1016\/j.eplepsyres.2019.106263","article-title":"Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam","volume":"160","author":"Savage","year":"2020","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2022.114238_bb0230","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.expneurol.2022.114238_bb0235","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2019.03.042","article-title":"Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol","volume":"95","author":"Szaflarski","year":"2019","journal-title":"Epilepsy Behav."},{"issue":"10125","key":"10.1016\/j.expneurol.2022.114238_bb0240","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114238_bb0245","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on Cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114238_bb0250","doi-asserted-by":"crossref","first-page":"23462","DOI":"10.1038\/s41598-021-02770-6","article-title":"Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis","volume":"11","author":"Treves","year":"2021","journal-title":"Sci. Rep."},{"issue":"4 Suppl 1","key":"10.1016\/j.expneurol.2022.114238_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5698\/1535-7597.18.4s1.1","article-title":"Summary of antiepileptic drugs available in the United States of America: working towards a world without epilepsy","volume":"18","author":"Vossler","year":"2018","journal-title":"Epilepsy Curr."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488622002631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488622002631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T06:12:22Z","timestamp":1758003142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488622002631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":50,"alternative-id":["S0014488622002631"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114238","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114238"}}